Epilepsy Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | ES Therapeutics, PhytoTech Therapeutics, Ltd., UCB Biopharma, SK Life Science, UCB Biopharma

The Key Epilepsy Companies in the market include - Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others.

DelveInsight's "Epilepsy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Epilepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Epilepsy Market Forecast [https://www.delveinsight.com/sample-request/epilepsy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Epilepsy Market Report:

*
The Epilepsy market size was valued ~USD 9 billion in 2023 and is anticipated to grow with a significant CAGR of 7% during the study period (2020-2034)

*
In May 2025, Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotech company focused on developing small molecule precision therapies for neurological and psychiatric conditions, announced its financial results for the first quarter ending March 31, 2025, along with a business update. The company described 2025 as a pivotal year, as it moves toward presenting initial proof-of-concept data for RAP-219 from its Phase 2a trial in patients with refractory focal epilepsy and advances its pipeline-in-a-product approach by launching a clinical trial for bipolar mania.

*
In April 2025, In a Phase Ib/IIa trial, Lundbeck's receptor superagonist, developed to treat seizures linked to developmental and epileptic encephalopathies (DEEs), demonstrated a 61.2% reduction in total seizures. Interim data from the open-label extension (OLE) of the Pacific trial (NCT05364021), which evaluated bexicaserin, an oral 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, in patients previously on placebo, revealed a 57.3% decrease in countable motor seizures and a 61.2% reduction in total seizures in those who had switched from placebo.

*
In March 2025, QurAlis Corporation, a clinical-stage biotechnology company focused on developing precision medicines for neurodegenerative and neurological diseases, announced positive topline results from its Phase 1 proof-of-mechanism (PoM) clinical trial of QRL-101. The study, conducted in healthy volunteers, assessed biomarkers associated with amyotrophic lateral sclerosis (ALS) and epilepsy.

*
In November 2024, uniQure N.V. (NASDAQ: QURE), a pioneering gene therapy company focused on developing treatments for severe medical conditions, has announced that the first patient has been administered AMT-260 in the GenTLE Phase I/IIa clinical trial for refractory mesial temporal lobe epilepsy (MTLE).

*
In September 2024, Synergia Medical successfully implanted its neurostimulation technology in the first two patients participating in a study aimed at treating epilepsy. These procedures are part of a first-in-human trial being conducted at two locations in Belgium and one in Germany. The surgeries for the initial patients were performed earlier this month at the Belgian sites, according to the company.

*
In 2023, the Epilepsy Treatment Market in the US was valued at around USD 4.3 billion, representing approximately 48% of the total market revenue across the 7MM.

*
In 2023, the Epilepsy Treatment Market in the EU4 and the UK held a market share of approximately 29%. Among these countries, Germany had the largest market share, followed by France and the UK. These figures are expected to evolve during the forecast period.

*
In 2023, the Epilepsy Treatment Market Size in Japan was estimated to be around USD 2.1 billion.

*
In 2023, the total diagnosed prevalent cases of epilepsy in the 7MM were approximately 7 million, with an expected compound annual growth rate (CAGR) of 0.4% through 2034.

*
In 2023, the US had around 3.3 million total diagnosed epilepsy cases, with 14% of them in children and 86% in adults. The total number of epilepsy cases is anticipated to rise by 2034.

*
In 2023, the EU4 and the UK had approximately 1.3 million male cases and 1.5 million female cases of diagnosed epilepsy, with these figures expected to increase over the study period.

*
In 2023, Germany reported the highest number of epilepsy cases among the EU4 and the UK, with approximately 735 thousand cases. Of these, nearly 74% were focal seizures, 18% were generalized seizures, and 8% were classified as other determined or undetermined epileptic seizures.

*
In 2023, Japan had the second-highest number of diagnosed epilepsy cases among the 7MM, with approximately 890 thousand cases. These numbers are anticipated to change over the course of the study period.

*
In Japan, drug-resistant epilepsy/refractory cases accounted for the highest number of epilepsy cases, with approximately 82 thousand in 2023, followed by photosensitivity and childhood absence epilepsy, each with 44 thousand cases. These figures are projected to change by 2034.

*
The epilepsy market is expected to experience steady growth, with a compound annual growth rate (CAGR) of around 7% projected from 2024 to 2034. This growth across the 7MM will be fueled by the launch of new therapies, including LIBERVANT (diazepam buccal film), XEN1101, COMFYDE (carisbamate), Lorcaserin (E2023), and Soticlestat (TAK-935), among others.

*
DelveInsight estimates that in 2023, there were around 7 million total diagnosed prevalent cases of epilepsy across the 7MM. Of these, 48% of the cases were in the US, 39% were in the EU4 and the UK, and 13% were in Japan.

*
Key Epilepsy Companies: Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others

*
Key Epilepsy Therapies: LIBERVANT (diazepam buccal film), EPIDIOLEX/EPIDYOLEX (cannabidiol), XCOPRI/ONTOZRY (cenobamate), AFINITOR DISPERZ/VOTUBIA (everolimus), XEN1101/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others

*
The Epilepsy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epilepsy pipeline products will significantly revolutionize the Epilepsy market dynamics.

Epilepsy Overview

Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. Seizures can vary in severity and may involve changes in behavior, consciousness, muscle control, or sensory perception. The condition can develop at any age and may result from various factors, including genetics, brain injury, infections, or structural brain abnormalities. Epilepsy is typically managed with medication, lifestyle adjustments, and sometimes surgery for more severe cases.

Get a Free sample for the Epilepsy Market Report

https://www.delveinsight.com/report-store/epilepsy-market [https://www.delveinsight.com/report-store/epilepsy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Epilepsy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Epilepsy Epidemiology Segmentation:

The Epilepsy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Epilepsy

*
Prevalent Cases of Epilepsy by severity

*
Gender-specific Prevalence of Epilepsy

*
Diagnosed Cases of Episodic and Chronic Epilepsy

Download the report to understand which factors are driving Epilepsy epidemiology trends @ Epilepsy Epidemiology Forecast [https://www.delveinsight.com/sample-request/epilepsy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Epilepsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epilepsy market or expected to get launched during the study period. The analysis covers Epilepsy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Epilepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Epilepsy Therapies and Key Companies

*
LIBERVANT (diazepam buccal film): Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)

*
EPIDIOLEX/EPIDYOLEX (cannabidiol): Jazz Pharmaceuticals

*
XCOPRI/ONTOZRY (cenobamate): SK Biopharmaceutical/Angelini Pharma/Ono Pharmaceutical

*
AFINITOR DISPERZ/VOTUBIA (everolimus): Novartis

*
XEN1101/Azetukalner: Xenon Pharmaceuticals

*
Soticlestat (TAK-935): Takeda/Ovid Therapeutics

*
BHV-7000 (KB-3061): Biohaven Pharmaceuticals/Knopp Biosciences

Discover more about therapies set to grab major Epilepsy market share @ Epilepsy Treatment Market [https://www.delveinsight.com/sample-request/epilepsy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Epilepsy Market Strengths

*
Growing Focus On Providing Seizure-Free Life To Fuel Innovations.

*
Growth in The Demand For Epileptic Seizures Treatment

Epilepsy Market Opportunities

*
Growing funding for R&D of epilepsy is also contributing as a factor for the market growth.

*
Rising neurological diseases among population will also propel the growth of the market Increasing brain injuries cases due to road accidents will also drive the growth of this market

Scope of the Epilepsy Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Epilepsy Companies: Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others

*
Key Epilepsy Therapies: LIBERVANT (diazepam buccal film), EPIDIOLEX/EPIDYOLEX (cannabidiol), XCOPRI/ONTOZRY (cenobamate), AFINITOR DISPERZ/VOTUBIA (everolimus), XEN1101/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others

*
Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies

*
Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Epilepsy Unmet Needs, KOL's views, Analyst's views, Epilepsy Market Access and Reimbursement

To know more about Epilepsy companies working in the treatment market, visit @ Epilepsy Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/epilepsy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Epilepsy Market Report Introduction

2. Executive Summary for Epilepsy

3. SWOT analysis of Epilepsy

4. Epilepsy Patient Share (%) Overview at a Glance

5. Epilepsy Market Overview at a Glance

6. Epilepsy Disease Background and Overview

7. Epilepsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Epilepsy

9. Epilepsy Current Treatment and Medical Practices

10. Epilepsy Unmet Needs

11. Epilepsy Emerging Therapies

12. Epilepsy Market Outlook

13. Country-Wise Epilepsy Market Analysis (2020-2034)

14. Epilepsy Market Access and Reimbursement of Therapies

15. Epilepsy Market Drivers

16. Epilepsy Market Barriers

17. Epilepsy Appendix

18. Epilepsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=epilepsy-market-dynamics-indicate-upward-trajectory-through-2034-reports-delveinsight-es-therapeutics-phytotech-therapeutics-ltd-ucb-biopharma-sk-life-science-ucb-biopharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.